EMPLOYMENT AGREEMENTEmployment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
of the Releasees hereto for any matter or circumstance concerning which the Releasors have released the Releasees under this Release Agreement. Further, the Releasors agree not to encourage any other person or suggest to any other person that he, she or it institute any legal action against the Releasees, and I hereby declare, confirm and undertake that, if the Releasors or anyone else in their name should deliver a claim as mentioned above, I shall reimburse the Releasees and anyone else on their behalf to the full extent of the sum of the legal expenses and legal fees incurred by them as a result of any such claim; and in the event that Releasors prevail in such legal action, then the Releasees shall reimburse such sum to Me or the Releasors. The Releasors hereby agree to waive the right to any relief (monetary or otherwise) in any action, suit or proceeding I may bring in violation of this Release Agreement.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations • New Jersey
This Amended and Restated Employment Agreement (this “Agreement”), dated as of February 7, 2018, is entered into by and among TEVA PHARMACEUTICALS USA, INC., a Delaware corporation (“Teva USA”), and CARLO DE NOTARISTEFANI (the “Executive”).
AWARD AGREEMENTAward Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Award Agreement (this “Agreement”), is made effective as of February 9, 2018, between Teva Pharmaceutical Industries Limited (the “Company”) and [ ] (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2015 Long-Term Equity-Based Incentive Plan (the “Plan”).
SETTLEMENT AGREEMENT AND MUTUAL RELEASESSettlement Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations • New York
This Settlement Agreement and Mutual Releases (the “Agreement”) is entered into as of January 31, 2018 (the “Effective Date”) by and between Teva Pharmaceutical Industries Ltd. (“Teva”) and Allergan plc (“Allergan”). Teva and Allergan shall be referred to collectively as the “Parties” and individually as a “Party.”
ACQUISITION FACILITY AMENDMENT TO SENIOR UNSECURED JAPANESE YEN TERM LOAN CREDIT AGREEMENTAcquisition Facility Amendment • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Acquisition Facility Amendment to Senior Unsecured Japanese Yen Term Loan Credit Agreement (this “Amendment”), dated as of 24 September 2015, is made and entered into by and among Teva Pharmaceutical Industries Limited (the “Parent”), Teva Holdings K.K. (the “Borrower”) and Mizuho Bank, Ltd., as Administrative Agent (with the consent of the Required Lenders (as defined in the Credit Agreement (as defined below))) (the “Administrative Agent”).
AWARD AGREEMENTAward Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Award Agreement (this “Agreement”), is made effective as of [•], between Teva Pharmaceutical Industries Limited (the “Company”) and [•] (the “Participant”), in [his / her] capacity as a member of the Company’s board of directors (the “Board”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2015 Long-Term Equity-Based Incentive Plan (the “Plan”).
RETENTION BONUS AGREEMENTRetention Bonus Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations • Pennsylvania
This Retention Bonus Agreement (“Agreement’’) is effective as of November 7, 2016 (“Effective Date”), by and between Hafrun Fridriksdottir (“Employee”) and Teva Pharmaceuticals USA, Inc. (“Teva” or “Company”).
Personal Employment AgreementPersonal Employment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This personal employment agreement (this “Agreement”), is entered into in Petach Tikwa, on this 22nd day of December, 2013 by and between TEVA PHARMACEUTICAL INDUSTRIES LTD, company number 520013954 an Israeli corporation at 5 Basel St., Petach Tikwa, Israel (the “Company”/“Teva”) and Mark Sabag, holder of I.D. no. 24649998 of 34 Mendale St., Kiryat Atta, Israel (the “Executive”).
Amendment to the Employment Agreement dated December 21st, 2011 by and between Teva Pharmaceuticals Europe B.V. and Rob KoremansEmployment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Amendment (this “Amendment”) is made this 30th day of October, 2012, by and among Teva Pharmaceuticals Europe B.V. (the “Company”) and Rob Koremans (the “Employee”) to the Employment Agreement entered into between the Company and Executive dated December 21st, 2011 (the “Agreement”).
SECOND AMENDMENTEmployment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Second Amendment (the “Second Amendment”) dated as of January 12, 2015, is entered into by and among Teva Pharmaceuticals Europe B.V. (the “Company”) and Rob Koremans (the “Employee”).
AWARD AGREEMENTAward Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Award Agreement (this “Agreement”), is made effective as of [•], between Teva Pharmaceutical Industries Limited (the “Company”) and [•] (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2015 Long-Term Equity-Based Incentive Plan (the ‘Plan’).
AWARD AGREEMENTAward Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Award Agreement (this ‘Agreement’), is made as of this [•] day of [•], 2015, between Teva Pharmaceutical Industries Limited (the ‘Company’) and [•] (the ‘Participant’). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2010 Long-Term Equity-Based Incentive Plan (the ‘Plan’).
AWARD AGREEMENTAward Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Award Agreement (this “Agreement”), is made effective as of [●] 2015, between Teva Pharmaceutical Industries Limited (the “Company”) and [●] (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2010 Long-Term Equity-Based Incentive Plan (the “Plan”).
THIS AGREEMENT is made on December 2011 BETWEEN: THE PARTIES AGREE AS FOLLOWS:Employment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
AWARD AGREEMENTAward Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Award Agreement (this “Agreement”), is made effective as of September 18, 2017, between Teva Pharmaceutical Industries Limited (the “Company”) and Mike McClellan (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2015 Long-Term Equity-Based Incentive Plan (the “Plan”).
July 19, 2017 Mike McClellanInterim Cfo Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
Dr. Fridriksdottir Hafrun Dear Hafrun:Master Purchase Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
As you know, on July 27, 2015, Teva entered into a Master Purchase Agreement (the “Agreement”) to acquire Allergan’s generics business. You are critical to the success of the business, and we are excited about working with you in the future. We recognize the uncertainty that a transaction of this type may create, and therefore we have chosen you as one of a small and select group of executives to receive additional protections in connection with the transaction, as set forth in this letter.
THIRD AMENDMENTEmployment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This third Amendment (the “Third Amendment”) is made on September 18, 2017, is entered into by and among Teva Pharmaceuticals Europe B.V. (the “Company”) and Rob Koremans (the “Employee”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations • New Jersey
AMENDMENT TO SENIOR UNSECURED REVOLVING CREDIT AGREEMENTSenior Unsecured Revolving Credit Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations • New York
This Amendment to Senior Unsecured Revolving Credit Agreement (this “Amendment”), dated as of July 21, 2016, is made and entered into by and among Teva Pharmaceutical Industries Limited (the “Parent”), Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Finance Netherlands III B.V., Teva Finance Services B.V., Teva Finance Services II B.V. and Teva Capital Services Switzerland GmbH (collectively, the “Borrowers”) and Citibank, N.A., as Administrative Agent (with the consent of the Required Lenders (as defined in the Credit Agreement (as defined below))) (the “Administrative Agent”).
Translation from the Hebrew Amendment to the Employment Agreement dated August 7th, 2008 by and between Teva Pharmaceutical Industries Ltd. and Eyal DeshehEmployment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Amendment (this “Amendment”) is made this __ day of October, 2012, by and among Teva Pharmaceutical Industries Ltd. (the “Company”) and Eyal Desheh, bearer of Israeli ID number 051220309 (the “Executive”) to the Employment Agreement entered into between the Company and Executive dated August 7th, 2008, as amended on August 7th, 2008 (the “Agreement”).
Addendum to Personal Employment AgreementAddendum to Personal Employment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
Further to your employment agreement with Teva as Chief Financial Officer dated August 7, 2008 (hereinafter the “Employment Agreement”) and as agreed between yourself and Teva’s CEO, we hereby confirm the following:
Employment AgreementEmployment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Employment Agreement (this “Agreement”) is entered into in Petach Tikwa on this day of February 2017, to be effective as of the 6 day of February, 2017 (the “Effective Date”), and is made by and between TEVA PHARMACEUTICAL INDUSTRIES LTD., an Israeli corporation located at 5 Basel Street, Petach Tikwa, Israel, Company No. 52-001395-4 (the “Company”), and Prof. Yitzhak Peterburg, ID No. 5051067/6, of 92 Nehar Hayarden St., Tal Shahar (“Employee”).
AWARD AGREEMENTAward Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Award Agreement (this “Agreement”), is made effective as of May 18, 2017, between Teva Pharmaceutical Industries Limited (the “Company”) and Carlo de Notaristefani (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2015 Long-Term Equity-Based Incentive Plan (the “Plan”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Amended and Restated Employment Agreement (the “Agreement”) is entered into in Israel on this 22 day of May 2015 (the “Effective Date”), and is made by and between TEVA PHARMACEUTICAL INDUSTRIES LTD., an Israeli corporation located at 5 Basel Street, Petach Tikwa, Israel (the “Company”), and Dr. Michael Hayden (“Employee”).
AWARD AGREEMENTAward Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Award Agreement (this “Agreement”), is made effective as of [●], between Teva Pharmaceutical Industries Limited (the “Company”) and [●] (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2015 Long-Term Equity-Based Incentive Plan (the “Plan”).
AWARD AGREEMENTAward Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Award Agreement (this “Agreement”), is made effective as of November 3, 2017, between Teva Pharmaceutical Industries Limited (the “Company”) and Kare Schultz (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2015 Long-Term Equity-Based Incentive Plan (the “Plan”).
Employment AgreementEmployment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Employment Agreement (this “Agreement”) is entered into in Petach Tikwa on this 15 day of January 2014, to be effective as of the 11 day of February, 2014 (the “Effective Date”), and is made by and between TEVA PHARMACEUTICAL INDUSTRIES LTD., an Israeli corporation located at 5 Basel Street, Petach Tikwa, Israel, Company No. 52-001395-4 (the “Company”), and Mr. Erez Vigodman, ID No. 056094477, of Sderot HaShoshanim 7, Tel Aviv (“Employee”).
Translation from the Hebrew Termination AgreementTermination Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
WHEREAS, the Employee has been employed by the Company since April 28, 2008 in the position of Chief Financial Officer (the “Position”); and
12/27/2017 Converted RSUs Award Agreement - ReviewSubstitute Award Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Substitute Award Agreement (this “Agreement”) is made effective as of August 2nd, 2016, between Teva Pharmaceutical Industries Limited (the “Company”) and Hafrun Fridriksdottir (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2015 Long-Term Equity-Based Incentive Plan (the “Plan”).
12/27/2017 Options Award Agreement—ReviewSubstitute Award Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Substitute Award Agreement (this “Agreement”) is made effective as of August 2nd, 2016, between Teva Pharmaceutical Industries Limited (the “Company”) and Hafrun Fridriksdottir (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2015 Long-Term Equity-Based Incentive Plan (the “Plan”).
AWARD AGREEMENTAward Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Award Agreement (this “Agreement”), is made effective as of [•], between Teva Pharmaceutical Industries Limited (the “Company”) and Hafrun Fridriksdottir (the “Participant”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned thereto in the Company’s 2015 Long-Term Equity-Based Incentive Plan (the “Plan”).
TERMINATION AGREEMENT (beëindigingsovereenkomst)Termination Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
Translation from the Hebrew Personal Employment AgreementPersonal Employment Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
WHEREAS, the Employee has been employed by the Company since April 28, 2008 (hereinafter the “Effective Date”) in the capacity of Chief Financial Officer; and
Indemnification and Release AgreementIndemnification Agreement • February 12th, 2018 • Teva Pharmaceutical Industries LTD • Pharmaceutical preparations
This Indemnification and Release Agreement (this “Indemnification Agreement”) is being entered into effective as of [●], pursuant to the resolutions of the Board of Directors (the “Board”) of Teva Pharmaceutical Industries Ltd., a company organized under the laws of the State of Israel (the “Company”), dated July 31, 2012 and the resolutions of the Human Resources and Compensation Committee of the Board, and the Audit Committee of the Board, each dated July 30, 2012.
